CI

At a glance

ClinicalIndex Comparison Record
N/ACompleted· 51,690 enrolled
Drug / intervention
apixaban +3 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT03441633
NCT03441633N/ACompleted
CompareCT.gov

APIXABAN DRUG UTILIZATION STUDY IN STROKE PREVENTION IN ATRIAL FIBRILLATION (SPAF)

Pfizer·observational·Posted Feb 22, 2018·Updated Jun 9, 2023

In Brief

An observational study evaluating apixaban, dabigatran, and 2 other interventions for Atrial Fibrillation. Completed, enrolled 51,690 participants across 1 site.

Detailed Summary

Apixaban is a direct anticoagulant, which inhibits the factor Xa. Its clinical efficiency in prevention of stroke and systemic embolism in adult patients with NVAF (non/valvular atrial fibrillation) was demonstrated as well as has shown better safety profile compared with warfarin. A Drug Utilization study will evaluate whether this drug has been used in accordance with the approved indication and recommendations described in the summary of product characteristics (SmPC) and estimate possible misuse or overuse apixaban.

Study Details

Study Typeobservational
Allocation--
Masking--
Primary Purpose--
ConditionsAtrial Fibrillation
CountriesSpain
Collaborators--

Timeline

N/ACompletedFinished
20162017201820192020202120222023202420252026
First PostedFeb 22, 2018
Enrollment StartFeb 18, 2016
Primary CompletionMar 8, 2017
TodayJul 2, 2026
Enrollment to primary: 1.1 yearsPosted 8.4 years ago

Interventions

apixabandrug

current or new medication

dabigatrandrug

current or new medication

VKAdrug

current or new medication

rivaroxabandrug

current or new medication